Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Novo Nordisk's Semaglutide Improves Liver Health in Non-Obese MASH Patients in Trial Analysis

By Public Technologies
  • Novo Nordisk will present new liver research on Wegovy and investigational efruxifermin at The Liver Meeting, November 5-9, 2026, in Denver.
  • A post-hoc analysis of the phase 3 ESSENCE trial found semaglutide improved liver health in non-obese participants with MASH.
  • Analyses from the phase 2b SYMMETRY trial showed efruxifermin improved liver scarring in participants with MASH cirrhosis, including those with cardiometabolic conditions.
  • The PLATINUM-Truveta retrospective study will present comparisons of semaglutide and resmetirom on liver enzymes and cardiometabolic markers in routine clinical practice.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.